Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia
Open Access
- 1 January 2024
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 13 (2) , e6953
Abstract
Background: The first‐generation BTK inhibitor ibrutinib is a standard‐of‐care therapy in the treatment of chronic lymphocytic leukemia (CLL) despite potential side effects that often lead to discontinuation.Methods: This study used 2013–2019 claims data to describe the incidence rate of adverse events (AEs) among elderly Medicare beneficiaries newly initiating ibrutinib for CLL.Results: The final sample contained 11,870 Medicare beneficiaries with CLL (mean age 77.2) newly initiating ibrutinib, of whom 65.2% discontinued over mean follow‐up of 2.3 years. The overall incidence rate of AEs was 62.5 per 1000 patient‐months for all discontinuers and 32.9 per 1000 patient‐months for non‐discontinuers. Discontinuers had a higher incidence rate of AEs per 1000 patient‐months compared with non‐discontinuers for all AEs examined, including infection (22.8 vs. 14.5), atrial fibrillation (15.1 vs. 7.0), anemia (21.9 vs. 14.5), and arthralgia/myalgia (19.5 vs. 13.6).Conclusion: In this first real‐world study of a national sample of elderly US patients treated with ibrutinib, we found a clear unmet need for improved management of ibrutinib‐related AEs and/or new treatments to improve real‐world outcomes in patients with CLL.Keywords
This publication has 13 references indexed in Scilit:
- Ibrutinib dose modifications in the management of CLLJournal of Hematology & Oncology, 2020
- Targeting BTK in CLL: Beyond IbrutinibCurrent Hematologic Malignancy Reports, 2019
- Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practiceLeukemia & Lymphoma, 2019
- Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysisAmerican Journal of Hematology, 2019
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLNew England Journal of Medicine, 2018
- Ibrutinib-Associated Atrial FibrillationJACC: Clinical Electrophysiology, 2018
- Patterns of Ibrutinib Use, Discontinuation, and Hospitalization Among Patients with Chronic Lymphocytic Leukemia (CLL) in a US Healthcare Claims DatabaseBlood, 2018
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysisHaematologica, 2018
- Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatmentAmerican Journal of Hematology, 2017
- Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experienceBlood, 2016